



Bwrdd Iechyd
Addysgu Powys
Powys Teaching
Health Board

Information Governance Team
Monnow Ward
Bronllys Hospital
Bronllys
Brecon
Powys LD3 0LY
Email: Powys.FOI@wales.nhs.uk
Tel: 01686 252159/01874 442071

Our ref: IG/FOI/23.R.385

13 November 2023

Sent via email to: [REDACTED]

Dear [REDACTED]

Request under the Freedom of Information Act 2000

I write further to your request for information which was received on 6 November 2023, to confirm, in accordance with S.1(1)(a) of the Freedom of Information Act 2000, that Powys Teaching Health Board (PTHB) does not hold the information that you require.

For ease of reference your request is set out below and our response follows:

Your Freedom of Information (FOI) Request:

Please see below a Freedom of Information request made by OPEN Health. Please answer the questions with regards to NHS patients, i.e., excluding patients that received treatment as part of clinical trials or private healthcare.

Patients with acute myeloid leukaemia (AML)

1. How many patients with AML, in total, have been treated with the following therapies during the last 6 months, irrespective of start date or line of therapy?

- Azacitidine monotherapy
- Low dose cytarabine (LoDAC) monotherapy
- Venetoclax + azacitidine
- Venetoclax + LoDAC
- Ivosidenib
- Intensive chemotherapy-based regimen
- Other

2. How many newly diagnosed patients with AML have started first-line treatment with the following therapies during the last 6 months?

- Azacitidine monotherapy

Pencadlys
Tŷ Glasbury, Ysbyty Bronllys,
Aberhonddu, Powys LD3 0LU
Ffôn: 01874 711661



Headquarters
Glasbury House, Bronllys Hospital
Brecon, Powys LD3 0LU
Tel: 01874 711661

Rydym yn croesawu gohebiaeth Gymraeg
Bwrdd Iechyd Addysgu Powys yw enw gweithred Bwrdd Iechyd Lleol
Addysgu Powys



We welcome correspondence in Welsh
Powys Teaching Health Board is the operational name of
Powys Teaching Local Health Board

- Low dose cytarabine (LoDAC) monotherapy
- Venetoclax + azacitidine
- Venetoclax + LoDAC
- Ivosidenib
- Intensive chemotherapy-based regimen
- Other

Note: this should only include patients who have started first-line treatment during the 6-month window.

3. Of the patients with AML treated with venetoclax (venetoclax + azacitidine or venetoclax + LoDAC) in the last 6 months, how many received treatment in line with National Institute for Health and Care Excellence guidance?

Patients with chronic lymphocytic leukaemia (CLL)

4. How many patients with CLL have received treatment with venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?

Note: this should include patients who started treatment prior to the 6-month window

5. How many patients with CLL who were new to all lines of treatment received venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?

Note: this should include only patients who have started treatment during the 6-month window

Powys Response:

Powys Teaching Health Board (PTHB) does not initiate treatment with any of the medicines listed; patients are treated by providers outside of Powys. PTHB commissions oncology services from several Welsh health boards and English provider organisations.

Due to the complex nature of PTHB’s commissioning arrangements, not all of our providers indicate the indication for use for each episode of care where these drugs are used. For this reason, PTHB does not hold the data relating to your request, however, the health board is working closely with providers to ensure that this information can be provided in the future. We therefore recommend that you approach our providers for this information directly:

Health Board/Organisation	FOI Contact Details
Gloucester Hospitals NHS Foundation Trust	ghn-tr.foi@nhs.net
Midlands Partnership NHS Foundation Trust	FOI@mpft.nhs.uk
Robert Jones Agnes Hunt	rjah.foi@nhs.net
Sandwell and West Birmingham NHS Trust	swb-tr.SWBH-GM-

	FOIRequests@nhs.net
Shrewsbury & Telford Hospital NHS Trust	https://www.sath.nhs.uk/about-us/freedom-of-information/make-an-enquiry/
The Royal Wolverhampton NHS Trust	rwh-tr.foi@nhs.net
Worcestershire Acute Hospitals NHS Trust	wah-tr.FOI@nhs.net
Wye Valley NHS trust	https://www.wyevalley.nhs.uk/about-us/information-requests.aspx

Health Board/Organisation	FOI Contact Details
Aneurin Bevan University Health Board	FOI.ABB@wales.nhs.uk
Betsi Cadwaladr University Health Board	bcu.foi@wales.nhs.uk
Cardiff & Vale University Health Board	FOI.Requests@wales.nhs.uk
Cwm Taf Morgannwg University Health Board	Freedomofinformation@wales.nhs.uk
Hywel Dda University Health Board	FOI.hyweldda@wales.nhs.uk
Swansea Bay University Health Board	FOIA.Requests@wales.nhs.uk
Velindre University Health Board	Foi.vunhst@wales.nhs.uk

Should you need any further assistance, please do not hesitate to contact me at the address below.

If you are dissatisfied, with the way your request has been dealt with by PTHB, you have the right to request a review in which case you should write to:

Chief Executive
 Powys Teaching Health Board Headquarters
 Glasbury House
 Bronllys Hospital
 Bronllys
 Brecon
 Powys LD3 0LY

If you are still dissatisfied at the end of the review, you may complain to the Information Commissioner, who can be contacted at the following address:

Information Commissioner's Office - Wales
 2nd Floor,
 Churchill House,
 Churchill Way,
 Cardiff, CF10 2HH
 Tel: 029 2067 8400 Fax 029 2067 8399
www.ico.org.uk twitter.com/iconews

Rydym yn croesawu derbyn gohebiaeth yng Nghymraeg. Byddwn yn ateb y fath ohebiaeth yng Nghymraeg ac ni fydd hyn yn arwain at oedi. We welcome receiving correspondence in Welsh. We will reply to such correspondence in Welsh and this will not lead to a delay.

Yours sincerely

A handwritten signature in black ink that reads "KL Wright". The signature is written in a cursive style with a horizontal line underneath the name.

Kate Wright
Medical Director